Search for: "AMGEN V HOECHST MARION ROUSSEL"
Results 1 - 20
of 48
Sort by Relevance
|
Sort by Date
30 Apr 2024, 7:30 am
Hoechst Marion Roussel, Inc., 314 F.3d 1313, 1354 (Fed.Cir.2003). [read post]
8 Mar 2023, 2:51 pm
Hoechst Marion Roussel, Inc., 314 F.3d 1313, 1330 (Fed. [read post]
17 Mar 2022, 2:32 pm
Hoechst Marion Roussel, Inc., 314 F.3d 1313 (Fed. [read post]
26 Aug 2021, 1:05 pm
Hoechst Marion Roussel, Inc., 314 F.3d 1313, 1330 (Fed. [read post]
9 Jun 2018, 7:01 pm
Hoechst Marion Roussel, Inc., 314 F.3d 1313,1354 (Fed. [read post]
3 Mar 2018, 4:02 am
It's now 13 years since Lord Hoffmann told us definitively how to interpret patents claims, in his opinion in Kirin Amgen v Hoechst Marion Roussel [2005] 1 All ER 667. [read post]
26 Jul 2017, 3:49 am
As explained in paragraph 42 of this judgment, in paragraph 37 of Kirin-Amgen Inc v Hoechst Marion Roussel Ltd [2005] RPC 9, Lord Hoffmann explained that the doctrine of equivalents had been developed in the United States. [read post]
26 Jul 2017, 3:49 am
As explained in paragraph 42 of this judgment, in paragraph 37 of Kirin-Amgen Inc v Hoechst Marion Roussel Ltd [2005] RPC 9, Lord Hoffmann explained that the doctrine of equivalents had been developed in the United States. [read post]
13 Jul 2017, 8:47 am
The judgment comes as a surprise, as the previously established UK case law had over time firmly done away with the idea of ‘pith and marrow’ infringement, culminating in the seminal House of Lords judgment in Kirin-Amgen v Hoechst Marion Roussel [2004] UKHL 46. [read post]
13 Jul 2017, 8:47 am
The judgment comes as a surprise, as the previously established UK case law had over time firmly done away with the idea of ‘pith and marrow’ infringement, culminating in the seminal House of Lords judgment in Kirin-Amgen v Hoechst Marion Roussel [2004] UKHL 46. [read post]
12 Jul 2017, 1:34 pm
Later, in Kirin-Amgen v Hoechst Marion Roussel [2005] RPC 9 Lord Hoffmann confirmed that purposive construction as in Catnic and Improver gave “effect to the requirements of the Protocol” and was “the bedrock of patent construction, universally applicable”, whereas the Protocol or Improver questions were simply “guidelines for applying that principle to equivalents ... , more useful in some cases than in others”.Having… [read post]
12 Jul 2017, 7:59 am
Later, in Kirin-Amgen v Hoechst Marion Roussel [2005] RPC 9 Lord Hoffmann confirmed that purposive construction as in Catnic and Improver gave “effect to the requirements of the Protocol” and was “the bedrock of patent construction, universally applicable”, whereas the Protocol or Improver questions were simply “guidelines for applying that principle to equivalents ... , more useful in some cases than in others”.Having… [read post]
6 Apr 2017, 1:35 pm
See Medicines Co. v. [read post]
26 Nov 2015, 8:12 am
Per the precedent set in Kirin-Amgen Inc v Hoechst Marion Roussel Ltd [2004] UKHL 46 (and other cases since), the question is "...what the person skilled in the art would have understood the Patentee to be using the language of the claim to mean". [read post]
19 Oct 2015, 1:39 pm
Hoechst Marion Roussel, Inc., 314F.3d 1313, 1354 (Fed. [read post]
30 Jul 2015, 9:50 am
That is what today's decision addresses.Appeal to the Supreme CourtThe Court of Appeal has refused leave for Smith & Nephew to appeal to the Supreme Court, because it considered that there is no significant point of general public importance at stake, since it has done no more than apply the established principles of claim construction from Kirin Amgen (Kirin Amgen Inc v Hoechst Marion Roussel Ltd [2004] UKHL 46, [2005] RPC 9) to… [read post]
12 Dec 2014, 10:29 pm
Hoechst Marion Roussel, Inc., 314 F.3d 1313, 1355-56 (Fed. [read post]
2 Feb 2014, 9:40 am
Hoechst Marion Roussel, Inc., 314 F.3d 1313, 1342 (Fed. [read post]
5 Mar 2013, 11:03 pm
Hoechst Marion Roussel (2005) RPC 169—a watershed decision—to the contribution made by the scientific advisor in that case. [read post]
5 Aug 2012, 9:04 pm
Hoechst Marion Roussel, Inc., 314 F.3d 1313, 1354 (Fed. [read post]
